Spruce Biosciences Expands Tildacerfont Portfolio with Potential Treatment for Polycystic Ovary Syndrome
Late-stage biopharmaceutical company Spruce Biosciences Inc (NASDAQ: SRPB) reported financial results for the second quarter ended June 30, 2021 and announced that it has submitted an investigational new drug application (IND) for tilda